The National Institute of Allergy and Infectious Diseases has stopped enrollment into a large international HIV/AIDS trial comparing continuous antiretroviral therapy with episodic drug treatment based on levels of CD4 cells.
Interim data from the trial, Strategies for Management of Anti-Retroviral Therapy, or SMART, revealed that patients receiving episodic therapy had twice the risk of disease progression, the major outcome of the study, as well as increases in major complications such as cardiovascular, kidney, and liver diseases.
Hampton T. HIV/AIDS Trial Stopped. JAMA. 2006;295(8):880. doi:10.1001/jama.295.8.880-a